Skip to content

Disappointing figures are presented.

E-prescription business fails to meet expectations, while overall revenue at DocMorris sees a 7.9% increase.

Poor performance indicated.
Poor performance indicated.

Disappointing figures are presented.

In a recent announcement, DocMorris, the online pharmacy giant, reported its second quarter results for the year. The company's revenue increased by 7.9% to CHF 572.1 million (EUR 607 million) in the first six months.

The growth was particularly strong in Germany, where the company generated CHF 538.6 million, an 8.2% increase over the previous year. The smaller European business also saw growth, with a 3.5% increase to CHF 33.5 million. Notably, the prescription e-prescription business experienced a significant boost, with revenue increasing by 40.5% to CHF 109.7 million.

However, the company faced challenges in other areas. Earnings before interest, taxes, depreciation, and amortization (EBITDA) adjusted for one-off items was -CHF 28.8 million, compared to -CHF 20.1 million in the previous year. This increase in loss is attributed to various one-off items, but the specifics were not disclosed.

DocMorris expects further acceleration in the second half of the year in its prescription e-prescription business, indicating a focus on this area for future growth.

Despite the positive growth in Germany, there seems to be some uncertainty regarding the company's operations in Redcare Pharmacy, as the name of the administrator overseeing the company is not explicitly mentioned in the available search results.

The second quarter ended with a net loss of CHF 61.6 million, a significant increase from the previous year's net loss of CHF 37.9 million. However, the company remains optimistic about its prospects for the rest of the year, particularly in its prescription e-prescription business.

In summary, while DocMorris faced challenges in certain areas, the company reported strong growth in its prescription e-prescription business and in Germany. The company remains optimistic about its prospects for the rest of the year, particularly in the prescription e-prescription business. The uncertainty surrounding Redcare Pharmacy remains to be addressed.

Read also:

Latest